71302-71-1

Basic information

• Product Name: 5-PYRROLIDINOAMYLAMINE
• Synonyms: 5-PYRROLIDINOAMYLAMINE;5-(pyrrolidin-1-yl)pentan-1-aMine;5-(Pyrrolidin-1-yl)pentylamine;1-PyrrolidinepentanaMine 2HCl
• CAS NO: 71302-71-1
• Molecular Formula: C₉H₂₀N₂
• Molecular Weight: 156.27
• Mol File: 71302-71-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 233.0±8.0℃ (760 Torr)
• Flash Point: 88.7±13.6℃
• Appearance: /
• Density: 0.916±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.0572mmHg at 25°C
• Refractive Index: 1.483
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 5-PYRROLIDINOAMYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-PYRROLIDINOAMYLAMINE(71302-71-1)
• EPA Substance Registry System: 5-PYRROLIDINOAMYLAMINE(71302-71-1)

Safety Data

• Hazardous Substances Data: 71302-71-1(Hazardous Substances Data)

Usage

General Description

5-PYRROLIDINOAMYLAMINE is a chemical compound with the molecular formula C10H21N2. It is a derivative of amphetamine and has stimulant properties, making it a potentially dangerous and controlled substance. The compound is also known by its street name "UPSA," and it is often abused for its euphoric and stimulating effects on the central nervous system. The use and distribution of 5-PYRROLIDINOAMYLAMINE are regulated and restricted in many countries due to its potential for abuse and addiction. The compound poses significant health risks, including increased heart rate, elevated blood pressure, and potential for overdose.

InChI:InChI=1/C9H20N2/c10-6-2-1-3-7-11-8-4-5-9-11/h1-10H2

Upstream product

• 928006-41-1 2-(5-(pyrrolidin-1-yl)pentyl)isoindoline-1,3-dione 
• 111-24-0 1,5-dibromo-pentane 
• 954-81-4 N-(5-bromopentyl)phthalimide 
• 71888-57-8 5-(pyrrolidin-1-yl)-pentanenitrile 

Downstream Products

• 1620401-82-2 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine 
• 1620401-83-3 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine trifluoroacetic acid 
• 928006-47-7 {3-biphenyl-4-yl-2-[methyl-(5-pyrrolidin-1-yl-pentyl)-amino]-3,4-dihydro-quinazolin-4-yl}-acetic acid 
• 928006-45-5 KYS₀₅₀₇₉ 
• 928006-46-6 {2-[methyl-(5-pyrrolidin-1-yl-pentyl)-amino]-3-phenyl-3,4-dihydro-quinazolin-4-yl}-acetic acid 
• 928006-44-4 KYS₀₅₀₇₆ 

Relevant articles and documents

Novel Multitarget Directed Triazinoindole Derivatives as Anti-Alzheimer Agents

The multifaceted nature of Alzheimer's disease (AD) demands treatment with multitarget-directed ligands (MTDLs) to confront the key pathological aberrations. A novel series of triazinoindole derivatives were designed and synthesized. In vitro studies revealed that all the compounds showed moderate to good anticholinesterase activity; the most active compound 23e showed an IC50 value of 0.56 ± 0.02 μM for AChE and an IC50 value of 1.17 ± 0.09 μM for BuChE. These derivatives are also endowed with potent antioxidant activity. To understand the plausible binding mode of the compound 23e, molecular docking studies and molecular dynamics simulation studies were performed, and the results indicated significant interactions of 23e within the active sites of AChE as well as BuChE. Compound 23e successfully diminished H2O2-induced oxidative stress in SH-SY5Y cells and displayed excellent neuroprotective activity against H2O2 as well as Aβ-induced toxicity in SH-SY5Y cells in a concentration dependent manner. Furthermore, it did not show any significant toxicity in neuronal SH-SY5Y cells in the cytotoxicity assay. Compound 23e did not show any acute toxicity in rats at doses up to 2000 mg/kg, and it significantly reversed scopolamine-induced memory deficit in mice model. Additionally, compound 23e showed notable in silico ADMET properties. Taken collectively, these findings project compound 23e as a potential balanced MTDL in the evolution process of novel anti-AD drugs.

Synthesis and biological evaluation of novel T-type calcium channel blockers

3,4-Dihydroquinazoline analogues substituted by N-methyl-N-(5-pyrrolidinopentyl)amine at the 2-position were synthesized and their blocking effects were evaluated for T- and N-type calcium channels. Compound 11b (KYS05080), compared to mibefradil (IC50 = 1.34 ± 0.49 μM), was about 5-fold potent (IC50 = 0.26 ± 0.01 μM) for T-type calcium channel (α1G) blocking and its selectivity of T/N-type was also improved (7.5 versus 1.4 of mibefradil).